.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has actually decided on Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 as well as measured another nine names in the area as overweight. The assets banking company stated in a details that it continues to believe “diabesity is set to become.